Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Tango Therapeutics (TNGX) EPS (Basic): 2020-2025

Historic EPS (Basic) for Tango Therapeutics (TNGX) over the last 6 years, with Sep 2025 value amounting to $0.14.

  • Tango Therapeutics' EPS (Basic) rose 151.85% to $0.14 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.91, marking a year-over-year increase of 21.55%. This contributed to the annual value of -$1.19 for FY2024, which is 10.19% down from last year.
  • As of Q3 2025, Tango Therapeutics' EPS (Basic) stood at $0.14, which was up 140.00% from -$0.35 recorded in Q2 2025.
  • In the past 5 years, Tango Therapeutics' EPS (Basic) registered a high of $0.14 during Q3 2025, and its lowest value of -$0.36 during Q1 2025.
  • Moreover, its 3-year median value for EPS (Basic) was -$0.30 (2023), whereas its average is -$0.26.
  • Its EPS (Basic) has fluctuated over the past 5 years, first slumped by 306,414.83% in 2021, then skyrocketed by 151.85% in 2025.
  • Tango Therapeutics' EPS (Basic) (Quarterly) stood at -$0.26 in 2021, then fell by 26.92% to -$0.33 in 2022, then climbed by 9.09% to -$0.30 in 2023, then dropped by 13.33% to -$0.34 in 2024, then skyrocketed by 151.85% to $0.14 in 2025.
  • Its EPS (Basic) stands at $0.14 for Q3 2025, versus -$0.35 for Q2 2025 and -$0.36 for Q1 2025.